DelveInsight forecasts that with the launch of 15+ emerging therapies alongside existing treatments, the ALS treatment market is anticipated to surpass USD 4 billion across the 7MM by 2034.
Currently, there is no cure for ALS and no effective treatment to halt or reverse the progression of the disease. As per our analysis, the diagnosed prevalent cases of ALS in the US were nearly 24K in 2023. Therefore, the management of ALS remains supportive and symptom-based. The approved drugs to treat ALS include RILUZOLE, RADICAVA, TIGLUTIK, EXSERVAN, and QALSODY. Riluzole, the first approved drug for the treatment of ALS, has since been recommended as first-line thera...
